3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Neoplasms
2
Head and Neck Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Laryngeal Diseases
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
Cisplatin
4
Cetuximab
4
pembrolizumab
3
Radiotherapy
2
Pemetrexed
2
N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide
2
monalizumab
1
capmatinib
1
Vitamin B 12
1
Tirapazamine
1
Tablets
1
Radiotherapy, Intensity-Modulated
1
LY2940680
1
Folic Acid
1
Fibroblast Growth Factor 7
1
Combined Modality Therapy
1
Carboplatin
1
Bleomycin
1
Allovectin-7
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Laryngeal Diseases
×
monalizumab
×
Clear all
NCT04590963
2026-06-01
INTERLINK-1
AstraZeneca
Phase 3
Active not recruiting
370 enrolled
21 charts